Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Or 11 + Dollars like it was back in 2.13.14 ? WOW!
Anyone think this could go to $ like it did in 8.1.16 ? $5.00 plus!!!
YA MAN! WHOO WHOOO HOOOOO GO DRUS!
He is on the ASK.01
Than SHE RUNS LIKE HELL!
Probably doubt that I am what you would call exempt.
Maybe you have them over your apartment :)
I just saw the Dr and he went flying by my house with the cops chasing him in a general lee looking car..... YEE HAAAAA - a bunch of money was flying out of the back - wonder where the ECK he got it al LOLOLOLO GLTA!
Hey you have to laugh a little why you MAKE A LOT!! :)
If the investors only new what they are getting in return GLTA LOLOLOL
Thank you FOR THE ENTERTAINMENT OF YET ANOTHER POS TICKER , HOPE ALL THE NEWBIES LEARNED A LESSON ON THIS TICKER LOL UNVC
Another pump and dump after seeing all the activity in my opinion. Wapos ticker. PROVE IT WRONG
Bro, show us completed real updates po filled with product
Purchase orders wecwant to see actual POs
I want to see purchase orders
They are stacking that ASK! 79 up DRUS
Looks ready to BLOW! DRUS
SPCL looks like we have some green honey dripping in baby! SPCL PIXEL whatever
it is what it is and i am here for the money honey BOOM USRM!
NICE BOUNCE BULLS! WE GOT THIS DRUS!
DRUS ME!
DRUS!
LOL! INND will make us RICH BABY! INND!
ITS SOMETHING :) GLTA
Learn to trade and do so by doing your own DD - Enjoy The heat in the Southwest :)
USRM NEWS!!!!!!!
SUNRISE, Fla. , Aug. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced results for its second quarter in 2018 -- the 10th consecutive quarter where revenue has increased.
For the quarter ending June 30, 2018 , the Company posted a revenue increase of 31% to $1.82m , up from $1.39m for the second quarter of last year. Revenue also increased for the six months ended June 30, 2018 , to $3.53m , up 39% from $2.54m for the same period last year.
Profit margin for the second quarter also increased, to 69% from 67% for the same period last year, and profit margin for the first six months of this year increased to 70% from 68% in the first six months of 2017. Gross profit was also up for both periods, with a 34% increase to $1.25m from $934k for the second quarter, and a 43% increase to $2.46m from $1.73m for the six-month period.
For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.
USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.
U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc. 13794 NW 4th Street , Suite 212 Sunrise, Fl 33325 Phone: 954.835.1500 Email: usstemcell@us-stemcell.com
View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-posts-profitable-results-for-second-quarter-2018-300694309.html
SOURCE U.S. Stem Cell, Inc.
SUNRISE, Fla. , Aug. 8, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced results for its second quarter in 2018 -- the 10th consecutive quarter where revenue has increased.
For the quarter ending June 30, 2018 , the Company posted a revenue increase of 31% to $1.82m , up from $1.39m for the second quarter of last year. Revenue also increased for the six months ended June 30, 2018 , to $3.53m , up 39% from $2.54m for the same period last year.
Profit margin for the second quarter also increased, to 69% from 67% for the same period last year, and profit margin for the first six months of this year increased to 70% from 68% in the first six months of 2017. Gross profit was also up for both periods, with a 34% increase to $1.25m from $934k for the second quarter, and a 43% increase to $2.46m from $1.73m for the six-month period.
For two consecutive years, USRM has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.
USRM has been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthopedic, autoimmune, degenerative and neurological diseases. USRM also trains and certifies physicians in stem cell therapy — to date, more than 700+ physicians worldwide — and has engaged with more than 288 clinics.
U.S. Stem Cell, Inc. is a leader in the regenerative medicine / cellular therapy industry specializing in physician training and certification and stem cell products including its lead product Adipocell™, as well as veterinary stem cell training, stem cell banking, and the creation and the management of stem cell clinics. To management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue", or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements and represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. The Company's business and the risks and uncertainties of the business are described in its filings with the Securities and Exchange Commission which can be found at sec.gov.
Media Contact: U.S. Stem Cell, Inc. 13794 NW 4th Street , Suite 212 Sunrise, Fl 33325 Phone: 954.835.1500 Email: usstemcell@us-stemcell.com
View original content with multimedia:http://www.prnewswire.com/news-releases/usrm-posts-profitable-results-for-second-quarter-2018-300694309.html
SOURCE U.S. Stem Cell, Inc.
WE HAVE NEWS FOLKS!!! NEWS !!!! JUST OUT!!! USRM
INND gonna go BOOM! INND!
YOU THINK ? LOL
You keep doing that - 2019 is around the corner LOL GO SANP
The SANPPPPP shark is a bloated pig.... put the glasses on and get out of the sandstorm she will tank like a sunken ship while you can GLTA
SANP GOT ALL YOUR MONEY - SAY THIS WITH US - I AM NOOOT GOOOD ATT HANDLING MONEY LOLOLOL GLTA
FOLKS they took all our money IMO and guess what lets start a new blog and gtfowolives :) FUSPCL
BBands showing it wants to RISE baby! ALL IN - DRUS!
MOved the BID up , BB indicate support to the north but it needs VOLUME to push this
Apparently - Someone said it was gonna go up soon - No CFGN or BMIC - Only a few Dilutors left lol - GLTA
That is NOT true.... what??? Q= Bankrupt??? NOT! LOLOL DRUS
She may hold , 3mm's holdn 32's SLAP EM! MMEX
TOLD YA! 32 's up
Push through the VWAP and she goes again SLAP HER! ASK!
nICE 2 MILLY SLAP ACGX!
At 65 dollars a share valuation #morespclbullchit;)) one would think , just maybe , I'm gonna say this real quietly.....it would be out of the greys.....lmmfao , glta baby